Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.4% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care Inc. (TNDM) specializes in diabetes management solutions, such as insulin pumps. Today, the stock market experienced a strong bearish movement.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.4% on Mar 30, 2026 14:05

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

[SCHEDULE 13G/A] TANDEM DIABETES CARE INC Amended Passive Investment Disclosure

The Vanguard Group filed an amended Schedule 13G/A for Tandem Diabetes Care, reporting 0 shares beneficially owned. This change is due to an internal realignment under SEC Release No. 34-39538, where certain subsidiaries will now report separately. This filing indicates a structural reporting change rather than an economic transaction like a sale or acquisition of securities.

https://www.stocktitan.net/sec-filings/TNDM/schedule-13g-a-tandem-diabetes-care-inc-amended-passive-investment-di-3ec4f418caf6.html

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into possible securities fraud involving Tandem Diabetes Care, Inc. The investigation follows a significant drop in Tandem's stock price on August 7, 2025, after the company disclosed a malfunction in its insulin pumps that could lead to discontinued insulin delivery and hyperglycemia. Investors are encouraged to contact the firm to discuss potential legal action.

https://www.globenewswire.com/news-release/2026/03/27/3263782/0/en/tandem-diabetes-care-inc-investigated-by-the-portnoy-law-firm.html

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into potential securities fraud involving Tandem Diabetes Care, Inc. This follows a significant 19.9% stock price drop on August 7, 2025, after Tandem disclosed a malfunction in its insulin pumps that could cease insulin delivery and lead to hyperglycemia. The firm is encouraging affected investors to contact them regarding their legal rights.

https://www.globenewswire.com/news-release/2026/03/27/3263782/0/en/Tandem-Diabetes-Care-Inc-Investigated-by-the-Portnoy-Law-Firm.html

Mizuho maintains Tandem Diabetes Care (TNDM) neutral recommendation

Mizuho has reiterated its neutral recommendation for Tandem Diabetes Care (TNDM), reflecting analysts' current stance on the company. This suggests Mizuho is neither bullish nor bearish on TNDM's stock performance at this time.

https://www.msn.com/en-us/money/topstocks/mizuho-maintains-tandem-diabetes-care-tndm-neutral-recommendation/ar-AA1SzlmX?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has received a consensus "Hold" rating from nineteen analysts, with an average 1-year price target of $29.22. Although the company beat Q4 earnings estimates, it remains unprofitable. Institutional investors have significantly increased their holdings in Tandem Diabetes Care.

https://www.marketbeat.com/instant-alerts/tandem-diabetes-care-inc-nasdaqtndm-receives-consensus-rating-of-hold-from-analysts-2026-03-27/

Trending Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.6% Today

Exxon Mobil Corporation ($XOM) Stock Forecast: Down 5.0% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.7% Today

Intel Corporation ($INTC) Stock Forecast: Up 8.8% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 6.9% Today

Hasbro Inc. ($HAS) Stock Forecast: Down 5.1% Today

Alcoa Corporation ($AA) Stock Forecast: Up 8.3% Today

The Boeing Company ($BA) Stock Forecast: Up 5.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.2% Today

Philip Morris International Inc ($PM) Stock Forecast: Down 5.0% Today

Tandem Diabetes Care, Inc. Price History

10.02.2026 - TNDM Stock was up 6.2%

• Tandem Diabetes Care's positive momentum is due to the launch of the Mobi insulin pump for Android users, expanding accessibility and convenience.
• The company's strategic move to make its Control-IQ+ technology compatible with a broader range of devices aligns with the industry's shift toward smartphone-operated automated insulin delivery systems.
• Favorable analyst attention, such as a price target increase and stock rating upgrade, has bolstered investor confidence in Tandem Diabetes Care's growth potential.
• With the recent completion of a $265 million convertible bond offering, the company's funding and valuation landscape has been reshaped, offering flexibility for future growth but also raising concerns about potential share dilution. It is advisable for investors to monitor the company's utilization of these funds in comparison to its current financial performance.

25.01.2026 - TNDM Stock was down 7.8%

• The disclosure of pricing and upsizing details of the private placement of convertible senior notes due in 2032 likely sparked investor worries about possible share dilution, contributing to the prevailing bearish sentiment.
• Despite the favorable development of a stock rating upgrade by Lake Street Capital Markets attributed to a successful transition to a pharmacy distribution model, the attention on the convertible notes offering appeared to overshadow the favorable shift in the company's business approach.
• Investors are possibly exercising caution regarding the company's intention to utilize the proceeds for potential acquisitions, raising uncertainties about future growth and profitability.
• Market response suggests that while the strategic shift's long-term advantages are acknowledged, immediate concerns regarding share dilution and capital deployment choices are exerting a negative influence on the stock's performance.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

27.01.2026 - TNDM Stock was down 5.1%

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

17.02.2026 - TNDM Stock was up 7.3%

• The positive movement in TNDM stock today could be linked to the company's new product releases, such as insulin pump software and the introduction of Tandem Mobi.
• Despite industry competition and economic challenges, TNDM's solid financial position and emphasis on advanced solutions appear to have appealed to investors.
• The recent net loss in the fourth quarter of 2025 might have been overlooked due to the perceived long-term growth prospects of Tandem Diabetes, contributing to the optimistic sentiment in the market today.

05.02.2026 - TNDM Stock was down 5.4%

• The introduction of Tandem Mobi's compatibility with Android smartphones, potentially broadening its user base, could have prompted concerns about technical issues or integration challenges, leading to uncertainty among investors and selling pressure on the stock.
• Despite receiving favorable analyst upgrades and surpassing $1 billion in worldwide sales, doubts voiced in the healthcare sector may have influenced market sentiment toward Tandem Diabetes Care, contributing to its recent stock decline.
• Anticipation surrounding the company's upcoming innovations in 2026, such as a tubeless Mobi pump and an enhanced insulin algorithm, may have raised expectations while also introducing uncertainty about execution and market reception, resulting in a negative impact on the stock price.
• When considering the expanded market reach, positive ratings, financial achievements, and industry doubts, the collective effect might have created varying investor sentiments, ultimately leading to the recent decline in TNDM stock value.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

03.02.2026 - TNDM Stock was down 5.7%

• A decline in TNDM stock value is likely due to investors selling their shares to lock in profits following a period of positive updates and price increases.
• Despite achieving over $1 billion in worldwide sales and receiving analyst rating upgrades, concerns of future financial obligations arose when the company issued $300 million in zero-coupon convertible notes due 2032, potentially leading to stock pullback.
• Mixed financial results, including a reported net loss for the half-year and challenges related to a high debt-equity ratio, may have further fueled the negative investor sentiment surrounding TNDM stock.

24.02.2026 - TNDM Stock was down 6.4%

• Despite recent positive developments, Tandem Diabetes Care (TNDM) saw a decrease in stock value.
• Investors may have been discouraged by the company's lack of profitability despite exceeding earnings and revenue projections, prompting some to realize profits.
• While analysts praised TNDM's pay-as-you-go pharmacy model, this alone may not have calmed market worries or profit expectations.
• The decline in stock value could be influenced by broader market trends or factors specific to Tandem Diabetes Care's industry performance.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

11.02.2026 - TNDM Stock was up 6.5%

• The bullish movement in TNDM stock today is due to the positive market reception of the company's expansion of the Mobi automated insulin delivery system to Android users. This move has significantly widened the potential user base for Tandem's technology, reflecting a strategic decision to tap into a larger market segment.
• Vanguard Group Inc.'s decision to trim its position in TNDM by 4.2% may have initially raised concerns among investors. However, the market sentiment was likely buoyed by the company's better-than-expected earnings report for the latest quarter, showcasing strong financial performance despite remaining unprofitable.
• The increased analyst attention, with Truist Securities raising its price target and Lake Street Capital Markets upgrading the stock to a Buy rating, also contributed to the positive momentum in TNDM stock, indicating growing confidence in the company's growth prospects and technological advancements in the diabetes management sector.
• Overall, Tandem Diabetes Care's strategic expansion into the Android market, coupled with favorable analyst ratings and robust financial performance, has fueled investor optimism and driven the bullish movement in the stock today.